40 results
8-K
EX-14.1
GYRE
Gyre Therapeutics Inc
30 Oct 23
Entry into a Material Definitive Agreement
5:17pm
to compliance with all applicable environmental laws, regulations, and industry best practices, such as those that affect hazardous waste disposal, emissions
DEFM14A
GYRE
Gyre Therapeutics Inc
20 Jul 23
Proxy related to merger
8:57am
materials, and may also produce hazardous waste products. Even if Catalyst contracts with third parties for the disposal of these materials and waste … . In addition, BC may be subject to fluctuations in other costs associated with BC’s production processes, such as costs of waste disposal, which
PRER14A
zpklxwsaje6a7rem9y
15 May 23
Preliminary revised proxy
4:02pm
PREM14A
wn09fepc
30 Mar 23
Preliminary proxy related to merger
4:48pm
425
EX-2.1
q3fcbgrrouqjp
27 Dec 22
Business combination disclosure
7:02am
425
EX-2.2
bkmq6nyfwf
27 Dec 22
Business combination disclosure
7:02am
8-K
EX-2.1
bc0ne3 teo2rl0dnrbbg
27 Dec 22
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
7:00am
8-K
EX-2.2
5274q14l6w16o2
27 Dec 22
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
7:00am
424B5
lde8q6ohmjo5
28 Jan 21
Prospectus supplement for primary offering
4:11pm
424B5
dgrr0ibbmktv
26 Jan 21
Prospectus supplement for primary offering
4:07pm
424B5
h1zuq
14 Feb 20
Prospectus supplement for primary offering
12:00am